Market Watch: ENDRA Life Sciences Provides Update on First Human Study


Market Watch featured the following release on StarFish Medical’s client, ENDRA Life Sciences Inc. which includes a quote on StarFish Medical.

December 17, 2018 (ACCESSWIRE via COMTEX) — Expands Study to 50 Subjects for Additional Data Collection

ANN ARBOR, MI / ACCESSWIRE / December 17, 2018 / ENDRA Life Sciences Inc. (”ENDRA”) NDRA, +16.67% a developer of enhanced ultrasound technologies, announced today that the Robarts Research Institute has completed its initial healthy subject enrollment and data collection of 25 subjects.

Dr. Aaron Fenster of Robarts Research Institute stated: ”I am pleased at the TAEUS device’s ease-of-use and the collaborative interaction between the Robarts Research Institute and ENDRA teams for ongoing improvement and workflow integration, in preparation for the Fatty Liver Imaging Probe (FLIP) system’s commercialization. While this is the first human subject testing with TAEUS technology, the ENDRA team, with support from its contractor, StarFish Medical, have clearly done their research homework in identifying user and patient needs and human factors. This rapidly-received approval of the study’s expansion allows us to maintain the study’s momentum and an additional 25 subjects would provide more data sets for TAEUS in support of an application for a CE mark,” concluded Dr. Fenster.

About ENDRA Life Sciences Inc.ENDRA Life Sciences Inc. (“ENDRA”)NDRA, +16.66% is a developer of enhanced ultrasound technologies. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI – at a fraction of the cost, and at the point-of-care. ENDRA’s first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA’s goal is to bring new capabilities to ultrasound – thereby broadening access to better healthcare. For more information, please visit

About Robarts Research Institute, Western University, Canada

Opened in 1986, Robarts Research Institute at Western University is a medical research facility in London, Ontario, with more than 600 people working to investigate some of the most debilitating diseases of our time, from heart disease and stroke to diabetes, Alzheimer’s and many forms of cancer.For more information, please visit

About MarketWatch

MarketWatch, published by Dow Jones & Co., tracks the pulse of markets for engaged investors with more than 16 million visitors per month. The site is a leading innovator in business news, personal finance information, real-time commentary and investment tools and data, with dedicated journalists generating hundreds of headlines, stories, videos and market briefs a day from bureaus in the U.S., Europe and Asia. In addition, MarketWatch offers subscription products for investors, including Retirement Weekly and ETF Trader.  MarketWatch is part of Dow Jones Media Group, which includes, Financial News London, Moneyish and Mansion Global.

Join over 6000 medical device professionals who receive our engineering, regulatory and commercialization insights and tips every month.